STOCK TITAN

[SCHEDULE 13G/A] Transcode Therapeutics, Inc. Amended Passive Investment Disclosure

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Transcode Therapeutics, Inc. received an amended Schedule 13G/A showing that Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz together report beneficial ownership of 41,601 shares of its common stock. This holding represents 4.9% of the outstanding common stock as of the event date 12/31/2025.

The reporting persons state they have no sole voting or dispositive power over these shares, but share voting and dispositive power over all 41,601 shares. They also certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Transcode Therapeutics, indicating a passive investment position below the 5% threshold.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



SABBY MANAGEMENT, LLC
Signature:/s/ Robert Grundstein
Name/Title:Chief Operating Officer
Date:01/07/2026
SABBY VOLATILITY WARRANT MASTER FUND LTD
Signature:/s/ Harry Thompson
Name/Title:Authorized Person of TDF Management Ltd., a Director
Date:01/07/2026
HAL MINTZ
Signature:/s/ Hal Mintz
Name/Title:Hal Mintz
Date:01/07/2026
Transcode Therapeutics Inc

NASDAQ:RNAZ

RNAZ Rankings

RNAZ Latest News

RNAZ Latest SEC Filings

RNAZ Stock Data

8.10M
832.42k
0.15%
4.43%
8.27%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON